102
Participants
Start Date
March 31, 2015
Primary Completion Date
November 7, 2016
Study Completion Date
February 6, 2019
Bendamustine
Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m\^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
Obinutuzumab
Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
Stony Brook University Hospital, Stony Brook
Center For Cancer and Blood Disorders, Bethesda
Virginia Cancer Specialists, PC, Fairfax
Northwest Georgia Oncology Centers PC - Marietta, Marietta
Piedmont Cancer Institute, PC, Atlanta
Clearview Cancer Institute, Huntsville
Southern Cancer Center - Mobile, Mobile
Fort Wayne Med Oncology & Hematology Inc, Fort Wayne
Cancer Care & Hematology; Specialists of Chicagoland, Niles
Highlands Oncology Group, Fayetteville
Texas Oncology-Tyler, Irving
Texas Oncology-Arlington, Arlington
Cancer Care Centers of South Texas-HOAST - San Antonio, New Braunfels
Joe Arrington Cancer Research & Treatment Center, Lubbock
Rocky Mountain Cancer Center - Aurora, Aurora
Cancer Care and Hematology, Fort Collins
Northern Utah Associates, Ogden
Ironwood Cancer TX & Rsch Ctrs, Chandler
Arizona Oncology Associates, PC - HAL, Tempe
Arizona Oncology Associates, PC - HOPE, Tucson
San Juan Oncology Associates, Farmington
Northwest Cancer Specialists - Portland (N Broadway), Portland
Oregon Health and Science University, Portland
Willamette Valley Cancer Insitute and Research Center, Springfield
Yakima Valley Memorial Hospital/North Star Lodge, Yakima
Regional Cancer Care Associates LLC - Morristown, Morristown
Lead Sponsor
Genentech, Inc.
INDUSTRY